Department of Bioethics, Clinical Center, National Institutes of Health, Bethesda, MD, USA.
Division of Ethics and Policy, School of Population and Global Health, McGill University, Montreal, QC, Canada.
Clin Trials. 2022 Apr;19(2):211-216. doi: 10.1177/17407745211063476. Epub 2022 Mar 29.
Pragmatic randomized clinical trials that compare two or more purportedly "within the standard of care" interventions attempt to provide real-world evidence for policy and practice decisions. There is considerable debate regarding their research risk status, which in turn could lead to debates about appropriate consent requirements. Yet no practical guidance for identifying the research risks of pragmatic randomized clinical trials is available.
We developed a practical, four-step process for identifying and evaluating the research risk of pragmatic trials that can be applied to those pragmatic randomized clinical trials that compare two or more "standard of care" or "accepted" interventions.
Using a variety of examples of standard of care pragmatic randomized clinical trials (ranging from trials comparing: insurance coverage conditions, patient reminders for health screens, intensive care unit procedures, post-stroke interventions, and drugs for life-threatening conditions), we illustrate in a four-step process how any pragmatic randomized clinical trial purportedly comparing standard interventions can be evaluated for their research risks.
Although determining the risk status of a standard of care pragmatic randomized clinical trial is only one necessary element in the ethical oversight of such pragmatic randomized clinical trials, it is a central element. Our four-step process of pragmatic randomized clinical trial risk determination provides a practical, transparent, and systematic approach with likely low risk of bias.
旨在比较两种或多种据称“符合标准治疗”的干预措施的实用随机临床试验试图为政策和实践决策提供真实世界的证据。关于它们的研究风险状况存在相当大的争议,这反过来又可能导致关于适当同意要求的争论。然而,对于识别实用随机临床试验的研究风险,尚无实用的指导。
我们开发了一种实用的、四步的方法来识别和评估实用试验的研究风险,该方法可应用于那些比较两种或多种“标准治疗”或“公认”干预措施的实用随机临床试验。
使用各种标准治疗实用随机临床试验的示例(包括比较以下内容的试验:保险覆盖条件、患者健康筛查提醒、重症监护病房程序、中风后干预和危及生命的疾病药物),我们以四步过程说明了如何评估任何据称比较标准干预措施的实用随机临床试验的研究风险。
虽然确定标准治疗实用随机临床试验的风险状况仅是此类实用随机临床试验伦理监督的必要要素之一,但它是一个核心要素。我们的实用随机临床试验风险确定四步过程提供了一种实用、透明和系统的方法,其偏倚风险可能较低。